March 2026 Research Update

This month included human reports suggesting that some TSC-related brain problems, and the related lung disease LAM, can show measurable improvement when treatment is started early or targeted to a specific situation, but the strength of evidence varied widely. A randomized trial in infants found fewer abnormal EEG patterns with early vigabatrin in some children, while small uncontrolled reports described improvement with sirolimus for LAM and seizure and skin changes with everolimus in a family case. Together, these studies add detail to who may benefit and where response may be limited, rather than changing the overall picture of TSC care. [1] [2] [3]

In infants with TSC, early vigabatrin was linked to fewer EEGs showing interictal epileptiform discharges (abnormal background electrical patterns between seizures) over 3 years compared with placebo. The difference was mainly seen in children who did not go on to develop epileptic spasms, while children who developed spasms had high rates of these EEG abnormalities in both groups. This helps clarify that early EEG changes may not improve equally for all infants, especially when spasms occur. [1]

For lymphangioleiomyomatosis (LAM), a lung disease that can occur with TSC or on its own, a small series described 5 women; the report did not say that any of them had TSC. Three who started sirolimus, an mTOR inhibitor, had improved symptoms and breathing-test results at follow-up, and the other two declined the proposed treatment. Because this report did not include a control group and outcomes were not complete for all patients, it mainly adds real-world examples of how LAM may be followed over time with symptoms, breathing tests, and chest imaging. It also reinforces that response can look different from person to person. [2]

A family case report described a person with a TSC2 splice-site variant who took everolimus (another mTOR-targeting medicine) and had fewer seizures and improvement in facial angiofibromas. This is an individual experience and cannot show what would happen for most people, but it adds to the broader understanding that mTOR-targeting treatments may affect both neurological symptoms and skin findings in some situations. The report also highlighted that a family member with the same variant had milder features, showing how variable TSC can be even within one family. [3]

The most directly informative result this month came from the randomized infant study, because it compared early vigabatrin with placebo and tracked EEG changes for several years. For families, it helps explain why researchers pay attention to early EEG changes and why outcomes may differ depending on whether epileptic spasms develop. The sirolimus and everolimus reports are smaller and uncontrolled, so they mainly add context about what improvement can look like and how varied responses can be, rather than providing a clear estimate of benefit. Important uncertainties remain about which individuals will respond best, and how EEG changes relate to long-term development and daily functioning. [1] [2] [3]

Several studies this month emphasized that TSC can be missed or incompletely characterized unless the right tests are used for the right question. In a 57-person imaging study, CT and routine MRI each detected different brain findings more reliably, and body CT showed how often organs beyond the brain can be involved. A separate case showed that blood genetic testing can be negative in mosaic TSC, and tumor-based testing can uncover the cause. Another case highlighted that CT-visible calcified lesions can sometimes point to seizure-causing brain tissue even when MRI looks normal. [4] [5] [6]

In the retrospective imaging comparison, CT was much better than routine MRI at detecting calcified subependymal nodules, while routine MRI was better at seeing cortical dysplasia (a type of brain development change). The study also reported that CT scans of the chest and abdomen identified a range of TSC-related findings outside the brain, including kidney angiomyolipomas and lung findings. The practical message is that different imaging tools can highlight different parts of TSC, which matters when trying to understand the full pattern of organ involvement. [4]

A case of mosaic TSC showed how a person can have subtle or limited skin signs and still have brain and kidney involvement, even when standard blood genetic testing is negative. Tissue-based testing from angiomyolipomas found a deep intronic TSC variant at very low levels, which supported the diagnosis of mosaicism. This adds a clear example of why some people can have TSC features without a detectable blood mutation, and why testing a tissue sample may sometimes provide the missing answer. [5]

In a child with drug-resistant epilepsy, CT showed calcified radial lesions that were not obvious as tubers on standard MRI, and seizure recording with implanted electrodes linked seizures to those CT lesions. Surgery removed the seizure-causing areas, and seizure control was maintained at 3 years in this single patient. This report adds an example where CT findings helped pinpoint an epilepsy target when MRI alone was not enough. [6]

These studies add to the understanding that diagnosing and fully mapping TSC is sometimes a step-by-step process, and different tests can answer different questions. For patients and caregivers, the new information is mainly about why results can look inconsistent across tests, such as a normal blood genetic test in mosaic TSC or a brain MRI that does not clearly show the seizure-causing area. The imaging study provides moderate-strength evidence that CT and routine MRI have complementary strengths, while the mosaic genetics and CT-guided epilepsy surgery examples are single-patient reports that illustrate possibilities rather than predict outcomes. What remains uncertain is how often these specific situations occur and which testing pathways are most helpful for an individual person. [4] [5] [6]

This month added clearer evidence that the burden of TSC on families is strongly shaped by behavior and seizures, and that delivering recommended follow-up across many specialties can be difficult even in expert settings. One study in families of preschoolers linked parenting stress to child behavior challenges, adaptive skills, seizure severity, and medical-related financial strain. Another study described real-world follow-up patterns and costs in a pediatric expert center, showing that imaging and neurology follow-up were closer to recommendations than many specialist visits. Together, these studies connect the medical side of TSC to practical strain on families and health systems. [7] [8]

In parents of 98 children ages 3 to 6 with TSC, higher parenting stress tracked with more child externalizing and internalizing behavior problems and social withdrawal. Lower adaptive skills (everyday function skills) also related to more stress, and so did seizure severity and financial problems related to medical care. This helps put numbers behind something many families report: stress is not only about medical diagnoses, but also about day-to-day behavior and practical supports. [7]

In a Paris pediatric TSC center, a review of 81 children found that full adherence to national recommendations for multidisciplinary follow-up was challenging. The report described a mix of clinic visits, teleconsultations, and day-hospital care, with an average annual cost of EUR 1344 per patient for consultations and hospitalizations, and higher costs in children with greater disability. This adds a real-world picture of how care can be organized and where gaps in specialist follow-up may arise. [8]

For families, these studies mainly add validation and clarity about what drives strain and what care often looks like in practice. The parenting stress study suggests that behavior challenges, lower everyday skills, seizures, and financial pressures often pile up together, which can help families and advocates describe needs more concretely. The care delivery study shows that even in an expert center, keeping up with every recommended specialist follow-up can be hard, while some types of monitoring like imaging and neurology visits may be easier to maintain. These findings are about understanding patterns rather than changing any individual care plan, and they do not identify a single best approach for reducing stress or improving follow-up. [7] [8]

The remaining papers were case reports or small case series, or early laboratory and animal studies, so they mainly add specific examples and research directions rather than answers that apply to most people. The case reports showed uncommon presentations and rare complications, including unusual skin or kidney findings and a delayed device-related event after epilepsy testing. The preclinical studies focused on how mTOR-related biology may shape brain cell activity, learning and generalization, and how signals in EEG could potentially reflect TSC-related changes in animal models. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18]

Across the case reports and small series, TSC-related findings sometimes appeared in unexpected ways or raised unusual diagnostic questions. One family report described a multicystic kidney pattern linked to a TSC1 variant, including an adult who progressed to end-stage kidney disease while the children had cysts but preserved kidney function. Another case described a child whose facial angiofibromas led to a new TSC diagnosis during an evaluation for suspected non-accidental injury. These reports reinforce that TSC can vary greatly and can sometimes be recognized through careful attention to skin and kidney findings. [11] [12]

Other clinical reports focused on rarer lesions or complications that can overlap with the broader TSC tumor spectrum. A 3-patient series described renal PEComas with a specific TFE3 gene fusion and noted additional mutations including TSC2, with short-term follow-up showing patients remained disease-free. A separate case described a solitary cutaneous angiomyolipoma removed without recurrence, emphasizing the role of tissue examination in diagnosis. These reports are mainly relevant as reminders that careful pathology and genetics can be important when unusual tumors appear. [13] [9]

One pediatric epilepsy case described a delayed complication after stereoelectroencephalography (SEEG), where retained electrode fragments later migrated to the spinal canal and into the brain ventricle, and one fragment was removed without complications. This is presented as the first reported case of concurrent brain and spinal migration of a retained SEEG fragment, making it an unusual event rather than an expected outcome. It adds a concrete example of why long-term imaging follow-up may sometimes detect unexpected device-related changes after invasive monitoring. [10]

The preclinical papers expanded tools and ideas about mTOR-related brain function but did not test outcomes in people with TSC. One lab platform used human stem cell-derived neurons to measure network activity at scale and reported partial reversal of a TSC-related activity pattern with a pharmacological intervention, without specifying a patient-facing outcome. Mouse studies explored (1) interpretable EEG features that predicted Tsc1 genotype without overt seizures, (2) how transient embryonic expression of a gene marker (RORg) changes interpretation of a Tsc1 seizure model, and (3) how Tsc2 changes in specific brain cells related to persistent generalization in a learning task. A separate mouse diabetes study connected gut microbiota changes to the AhR/TSC2/mTORC1 pathway, showing how TSC-related signaling intersects with metabolism in animals. [14] [15] [16] [17] [18]

For most patients and caregivers, this set of studies is best read as a collection of specific examples and early-stage research. The case reports can help people recognize that TSC can present subtly, vary within families, and occasionally intersect with rare tumors or unusual complications, but they cannot tell how likely these events are. The laboratory and animal studies may matter later because they build tools for measuring brain cell activity and clarify how mTOR-related pathways affect behavior, EEG patterns, and metabolism, yet they do not predict what will happen in an individual person with TSC. The main uncertainty is how these early signals will translate into better diagnosis, monitoring, or treatments in future human studies. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18]